Author: IQ TIMES MEDIA
In a historic first, San Francisco’s city attorney has filed a lawsuit against some of the largest U.S. manufacturers of ultra-processed foods that he says have made Americans sick.The companies named in the lawsuit, obtained and reviewed by ABC News, include Kraft Heinz, Mondelez, Post, Coca-Cola, PepsiCo, General Mills, Nestle, Kellanova, Kellogg, Mars,and ConAgra.City Attorney David Chiu spoke at a press conference at San Francisco City Hall on Tuesday surrounded by a table of popular products from crackers and breakfast cereals to frozen dinners and frosting to announce the legal action against the 10 food and drink corporations.Chiu said the…
The city of San Francisco filed a lawsuit against some of the nation’s top food manufacturers on Tuesday, arguing that ultraprocessed food from the likes of Coca-Cola and Nestle are responsible for a public health crisis.City Attorney David Chiu named 10 companies in the lawsuit, including the makers of such popular foods as Oreo cookies, Sour Patch Kids, Kit Kat, Cheerios and Lunchables. The lawsuit argues that ultraprocessed foods are linked to diseases such as Type 2 diabetes, fatty liver disease and cancer.“They took food and made it unrecognizable and harmful to the human body,” Chiu said in a news…
A biopharmaceutical company is looking for ways to slim down household pets.Okava Pharmaceuticals, a San Francisco based company, plans to introduce on Tuesday a new GLP-1 clinical weight loss study for cats.MEOW-1, as the study is called, will look to use OKV-119, a miniature implant, in cats which will deliver the GLP-1, continuously for up to six months.According to Okava, MEOW-1 is the first-ever weight loss trial using this approach on household pets.Eli Lilly’s next generation weight loss drug shows promise, early trial results suggestThe study will examine up to 50 cats who will take the implant and have their…
Amazon Web Services’ annual tech conference AWS re:Invent has wrapped up its first official day of programming and has already delivered an endless stream of product news. The unsurprising theme is AI for the enterprise, although this year it’s all about upgrades that give its customers greater control to customize AI agents — including one that AWS claims can learn from you and then work independently for days. AWS re:Invent 2025, which runs through December 5, started with a keynote from AWS CEO Matt Garman, who leaned into the idea that AI agents can unlock the “true value” of AI.…
Amazon announced a new product Tuesday called “AI Factories” that allows big corporations and governments to run its AI systems in their own data centers. Or as AWS puts it: Customers supply the power and the data center, and AWS plunks in the AI system, manages it, and can tie it into other AWS cloud services. The idea is to cater to companies and governments concerned with data sovereignty, or absolute control over their data so it can’t wind up in a competitor’s or foreign adversary’s hands. An on-prem AI Factory means not sending their data to a model maker…
Federal vaccine advisers selected by Health Secretary Robert F. Kennedy Jr. are planning to vote on ending the practice of vaccinating all newborns for hepatitis B and to examine whether shots on the childhood immunization schedule are behind the rise of allergies and autoimmune disorders, the newly appointed chair of the group told The Washington Post.Kirk Milhoan, a pediatric cardiologist and critic of coronavirus vaccination who recently took over as chair of the influential vaccine panel, said members meeting on Thursday and Friday are broadly scrutinizing vaccines recommended for children. The wide-ranging discussions on the timing of vaccines and ingredients…
As OpenAI goes into “Code Red” over competitive pressures, Google announced it has begun testing a new feature that merges its AI Overviews with AI Mode in Search. That means that users who are provided with the now common AI-generated snapshot of key information on a topic or question above their search results can choose to go deeper by asking follow-up questions in a conversational interface. Google calls this conversational feature AI Mode. It launched to U.S. users this May, and to global users this August, allowing for back-and-forth chats with Google’s Gemini AI, in an experience similar to ChatGPT.…
Amazon Web Services on Tuesday announced three new AI agents it calls “frontier agents,” including one designed to learn how you like to work and then operate on its own for days. Each of these agents handle different tasks such as writing code, security processes like code reviews, and automating DevOps tasks such as preventing incidents when pushing new code live. Preview versions of the agents are available now. Perhaps the biggest and most interesting claim by AWS is its promise that the frontier agent called “Kiro autonomous agent” can work on its own for days at a time. Kiro…
The city of San Francisco on Tuesday sued 10 major food companies, alleging that they marketed and sold ultraprocessed foods that they knew were harmful to human health and had been designed to be addictive.The lawsuit argues that the foods have contributed to a public health crisis in San Francisco and across the nation, saddling cities and other governments with medical costs associated with the consequences of diets high in processed food. It’s a first-of-its-kind attempt to hold food conglomerates accountable for the proliferation of these foods and their established health risks.“We have reached a tipping point in the scientific…
By Deena BeasleySAN DIEGO Dec 2 (Reuters) – Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer’s patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo’s studies had design flaws.Although the trials failed to show statistically significant slowing of cognitive decline in patients given the drug, “we still think it was the right decision… a scientific question that needed an answer,” Peter Johannsen, Novo’s international medical vice president, said in an address at the Clinical Trials in Alzheimer’s Disease meeting in San Diego.Data,…